Immunoglobulin A Nephropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – IgA Nephropathy (US)

IgA nephropathy (IgAN), also known as Berger’s disease, is a rare autoimmune condition that causes the accumulation of IgA in the kidney glomeruli, causing inflammation and damage to the kidneys. Initial treatment of IgAN predominantly comprises supportive care using RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance of the surrogate clinical trial endpoint “reduction in proteinuria” has enabled accelerated approval of novel IgAN therapies, leading to early market entries and the potential for rapid evolution of the therapeutic landscape. Under this scheme, the FDA approved Calliditas Therapeutics’ Tarpeyo (DR-budesonide), Travere Therapeutics’ Filspari (sparsentan), and Novartis’s Fabhalta (iptacopan). Tarpeyo and Filspari are now fully approved therapies in the United States. This report examines how the established and newly launched immunosuppressive and non-immunosuppressive therapies are being used to treat newly diagnosed and recently treated IgAN patients.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IgAN patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IgAN patients?
• How has Filspari been integrated into the treatment algorithm, and what is its source of business?
• What percentage of IgAN patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of IgAN patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Geography: United States

Key drugs: Tarpeyo (budesonide delayed-release), Filspari (sparsentan), RAAS inhibitors, SGLT-2 inhibitors (Jardiance, Farxiga, Invokana), corticosteroids.

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses